pmv pharmaceuticals inc - PMVP

PMVP

Close Chg Chg %
1.34 0.03 2.24%

Open Market

1.37

+0.03 (2.24%)

Volume: 72.40K

Last Updated:

Sep 9, 2026, 11:35 AM EDT

Company Overview: pmv pharmaceuticals inc - PMVP

PMVP Key Data

Open

$1.34

Day Range

1.34 - 1.39

52 Week Range

1.02 - 1.88

Market Cap

$97.41M

Shares Outstanding

75.51M

Public Float

69.23M

Beta

1.37

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.41

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

653.58K

 

PMVP Performance

1 Week
 
3.88%
 
1 Month
 
12.61%
 
3 Months
 
20.72%
 
1 Year
 
8.94%
 
5 Years
 
-95.64%
 

PMVP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About pmv pharmaceuticals inc - PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

PMVP At a Glance

PMV Pharmaceuticals, Inc.
400 Alexander Park Drive
Princeton, New Jersey 08540
Phone 1-609-642-6670 Revenue 0.00
Industry Biotechnology Net Income -77,742,000.00
Sector Health Technology Employees 54
Fiscal Year-end 12 / 2026
View SEC Filings

PMVP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.637
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.539
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.018

PMVP Efficiency

Revenue/Employee N/A
Income Per Employee -1,439,666.667
Receivables Turnover N/A
Total Asset Turnover N/A

PMVP Liquidity

Current Ratio 10.094
Quick Ratio 10.094
Cash Ratio 9.894

PMVP Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -50.506
Return on Equity -55.373
Return on Total Capital -73.654
Return on Invested Capital -55.123

PMVP Capital Structure

Total Debt to Total Equity 0.80
Total Debt to Total Capital 0.794
Total Debt to Total Assets 0.719
Long-Term Debt to Equity 0.415
Long-Term Debt to Total Capital 0.412
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pmv Pharmaceuticals Inc - PMVP

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
650.00K 1.26M 1.14M 133.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
650.00K 1.26M 1.14M 133.00K
Depreciation
650.00K 1.26M 1.14M 133.00K
Amortization of Intangibles
- - - -
-
COGS Growth
-49.26% +93.38% -8.99% -88.37%
Gross Income
(650.00K) (1.26M) (1.14M) (133.00K)
Gross Income Growth
+49.26% -93.38% +8.99% +88.37%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
76.39M 78.88M 84.30M 86.07M
Research & Development
51.67M 54.63M 57.38M 69.74M
Other SG&A
24.72M 24.25M 26.92M 16.33M
SGA Growth
+33.99% +3.25% +6.88% +2.10%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(77.04M) (80.13M) (85.45M) (86.21M)
Non Operating Income/Expense
3.71M 11.17M 10.64M 6.29M
Non-Operating Interest Income
3.63M 11.17M 10.65M 6.34M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(73.33M) (68.96M) (74.81M) (79.91M)
Pretax Income Growth
-26.81% +5.96% -8.48% -6.82%
Pretax Margin
- - - -
-
Income Tax
(9.00K) 2.00K (16.10M) (2.17M)
Income Tax - Current - Domestic
(9.00K) 2.00K (16.17M) (2.19M)
Income Tax - Current - Foreign
- - 70.00K 22.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(73.32M) (68.96M) (58.71M) (77.74M)
Minority Interest Expense
- - - -
-
Net Income
(73.32M) (68.96M) (58.71M) (77.74M)
Net Income Growth
-26.75% +5.94% +14.87% -32.42%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(73.32M) (68.96M) (58.71M) (77.74M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(73.32M) (68.96M) (58.71M) (77.74M)
EPS (Basic)
-1.608 -1.4362 -1.1382 -1.4796
EPS (Basic) Growth
-25.47% +10.68% +20.75% -29.99%
Basic Shares Outstanding
45.59M 48.01M 51.58M 52.54M
EPS (Diluted)
-1.608 -1.4362 -1.1382 -1.4796
EPS (Diluted) Growth
-25.47% +10.68% +20.75% -29.99%
Diluted Shares Outstanding
45.59M 48.01M 51.58M 52.54M
EBITDA
(76.39M) (78.88M) (84.30M) (86.07M)
EBITDA Growth
-33.99% -3.25% -6.88% -2.10%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 4.00
Number of Ratings 5 Current Quarters Estimate -0.343
FY Report Date 09 / 2026 Current Year's Estimate -1.195
Last Quarter’s Earnings -0.34 Median PE on CY Estimate N/A
Year Ago Earnings -1.48 Next Fiscal Year Estimate -0.895
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate -0.34 -0.28 -1.20 -0.90
High Estimates -0.25 -0.18 -0.93 -0.61
Low Estimate -0.41 -0.36 -1.42 -1.15
Coefficient of Variance -19.57 -30.30 -21.07 -32.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 4 4
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Pmv Pharmaceuticals Inc - PMVP

Date Name Shares Transaction Value
Oct 28, 2025 OrbiMed Advisors Private Equity 4,975,291 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.52 per share 7,562,442.32

Pmv Pharmaceuticals Inc in the News